107 related articles for article (PubMed ID: 9627339)
1. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies.
Diederichs CG; Staib L; Glatting G; Beger HG; Reske SN
J Nucl Med; 1998 Jun; 39(6):1030-3. PubMed ID: 9627339
[TBL] [Abstract][Full Text] [Related]
2. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
[TBL] [Abstract][Full Text] [Related]
4. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.
Diederichs CG; Staib L; Vogel J; Glasbrenner B; Glatting G; Brambs HJ; Beger HG; Reske SN
Pancreas; 2000 Mar; 20(2):109-16. PubMed ID: 10707924
[TBL] [Abstract][Full Text] [Related]
5. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
6. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.
Higashi T; Tamaki N; Torizuka T; Nakamoto Y; Sakahara H; Kimura T; Honda T; Inokuma T; Katsushima S; Ohshio G; Imamura M; Konishi J
J Nucl Med; 1998 Oct; 39(10):1727-35. PubMed ID: 9776278
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.
Zimny M; Bares R; Fass J; Adam G; Cremerius U; Dohmen B; Klever P; Sabri O; Schumpelick V; Buell U
Eur J Nucl Med; 1997 Jun; 24(6):678-82. PubMed ID: 9169578
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.
Reske SN; Grillenberger KG; Glatting G; Port M; Hildebrandt M; Gansauge F; Beger HG
J Nucl Med; 1997 Sep; 38(9):1344-8. PubMed ID: 9293784
[TBL] [Abstract][Full Text] [Related]
10. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.
Higashi T; Tamaki N; Honda T; Torizuka T; Kimura T; Inokuma T; Ohshio G; Hosotani R; Imamura M; Konishi J
J Nucl Med; 1997 Sep; 38(9):1337-44. PubMed ID: 9293783
[TBL] [Abstract][Full Text] [Related]
11. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
[TBL] [Abstract][Full Text] [Related]
12. Detection of liver metastases from pancreatic cancer using FDG PET.
Fröhlich A; Diederichs CG; Staib L; Vogel J; Beger HG; Reske SN
J Nucl Med; 1999 Feb; 40(2):250-5. PubMed ID: 10025831
[TBL] [Abstract][Full Text] [Related]
13. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
14. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
Voth M; Opfermann T; Gottschild D
Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
[TBL] [Abstract][Full Text] [Related]
15. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of pancreatic carcinoma: role of FDG PET.
Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
[TBL] [Abstract][Full Text] [Related]
17. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
Zimny M; Schumpelick V
Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.
Roelcke U; Blasberg RG; von Ammon K; Hofer S; Vontobel P; Maguire RP; Radü EW; Herrmann R; Leenders KL
J Nucl Med; 1998 May; 39(5):879-84. PubMed ID: 9591593
[TBL] [Abstract][Full Text] [Related]
19. Simple quantification of skeletal muscle glucose utilization by static 18F-FDG PET.
Yokoyama I; Inoue Y; Moritan T; Ohtomo K; Nagai R
J Nucl Med; 2003 Oct; 44(10):1592-8. PubMed ID: 14530472
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
